Selecting the right patients for gene-based therapies: Development and implementation of a pathogenicity scoring system combined with functional in vitro validation of gene variants and genotypes in patients with inherited retinal dystrophy as a criterion

选择合适的患者进行基于基因的治疗:以遗传性视网膜营养不良患者的基因变异和基因型的功能性体外验证相结合的致病性评分系统的开发和实施为标准

基本信息

项目摘要

The number of gene therapy trials for inherited retinal dystrophies is steadily increasing. It is important to ensure that the disease in these patients is truly and exclusively caused by the mutations in the target gene of gene therapy. Current practice for selecting patients for gene therapy in terms of genotype or its validity is neither objective nor standardised. Guidelines for variant interpretation in genetic diagnostics need to be further developed and standardised on a subject-specific basis. An objective and reliable pathogenicity assessment for individual variants and patient genotypes needs to be undertaken as an essential criterion for selecting patients into genotype-based therapy trials. In the first funding period, we correlated the scoring system for individual variants and patient genotypes as a proof-of-concept with functional data from our further developed in vitro aequorin-based bioassay for functional testing of missense variants in CNGA3. In the sequel application, we will first transfer this bioassay to CNGB3, and then to CNGA1 and CNGB1. We will again test the functionality of CNG channels with all previously uncharacterised putative disease-causing missense variants in a medium-throughput format in HEK293 cells. With this approach, we can evaluate all non-functionally characterised variants and confirm or reject the in silico prediction. At the end of the SPP, we expect to have an objective functionally confirmed pathogenicity assessment for all CNGA3, CNGB3, CNGA1 and CNGB1 variants observed in our patient cohort, literature and various mutation databases. This will allow patients to be prioritized and selected for future gene therapy trials for autosomal recessive achromatopsia – in the case of biallelic mutations in CNGA3 or CNGB3, and autosomal recessive Retinitis pigmentosa – in the case of biallelic mutations in CNGA1 or CNGB1.
遗传性视网膜营养不良的基因治疗试验数量正在稳步增加。重要的是要确保这些患者的疾病是真正和唯一地由基因治疗的目标基因突变引起的。目前根据基因型或其有效性选择患者进行基因治疗的做法既不客观,也不标准化。遗传诊断学中的变异解释指南需要在特定学科的基础上进一步制定和标准化。需要对个体变异和患者基因类型进行客观和可靠的致病性评估,作为选择患者参加基于基因的治疗试验的基本标准。在第一个资助期,我们将单个变异体和患者基因类型的评分系统作为概念验证与我们进一步开发的基于Aequorin的体外生物测试的功能数据相关联,用于CNGA3错义变异体的功能测试。在后续应用中,我们将首先将该生物测定转移到CNGB3,然后转移到CNGA1和CNGB1。我们将再次在HEK293细胞中测试CNG通道的功能,使用所有以前未确定的假定致病错义变体,以中等吞吐量格式。使用这种方法,我们可以评估所有非功能特征的变体,并确认或拒绝电子预测。在SPP结束时,我们希望对在我们的患者队列、文献和各种突变数据库中观察到的所有CNGA3、CNGB3、CNGA1和CNGB1变体进行客观的功能确认的致病性评估。这将允许优先选择患者进行未来常染色体隐性色盲的基因治疗试验-在CNGA3或CNGB3双等位基因突变的情况下,以及常染色体隐性视网膜色素变性的双等位基因突变的情况下-CNGA1或CNGB1的双等位基因突变的情况下。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dr. Susanne Kohl其他文献

Dr. Susanne Kohl的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dr. Susanne Kohl', 18)}}的其他基金

Molekulare Genetik hereditärer Zapfen- und Zapfen-Stäbchen-Dystrophien
遗传性视锥细胞和视杆细胞营养不良的分子遗传学
  • 批准号:
    13082978
  • 财政年份:
    2005
  • 资助金额:
    --
  • 项目类别:
    Clinical Research Units

相似国自然基金

中医药应对突发公共卫生事件循证指南报告规范的研制:一项基于RIGHT框架的方法学研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
几种新物理模型中的黑格斯粒子唯象研究
  • 批准号:
    11105116
  • 批准年份:
    2011
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Uncertainty aware virtual treatment planning for peripheral pulmonary artery stenosis
外周肺动脉狭窄的不确定性虚拟治疗计划
  • 批准号:
    10734008
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Platelet Metabolic Stress Induces Thrombo-Inflammation to Drive Endothelial Dysfunction in PH
PH 中血小板代谢应激诱导血栓炎症导致内皮功能障碍
  • 批准号:
    10736724
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
The cardiovascular consequences of sleep apnea plus COPD (Overlap syndrome)
睡眠呼吸暂停加慢性阻塞性肺病(重叠综合征)对心血管的影响
  • 批准号:
    10733384
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Early Detection of Right Ventricular Dysfunction and Emerging Pulmonary Hypertension in Systemic Sclerosis
系统性硬化症患者右心室功能障碍和肺动脉高压的早期发现
  • 批准号:
    10585312
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Mechanisms of outflow tract morphogenesis regulated by extracellular matrix
细胞外基质调控流出道形态发生的机制
  • 批准号:
    10720451
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Proteomic Signatures Associated with Right Ventricular Failure and Mortality in Pulmonary Arterial Hypertension
与肺动脉高压右心室衰竭和死亡率相关的蛋白质组学特征
  • 批准号:
    10675409
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary Hypertension
REVAMP-PH:重新利用缬沙坦可以预防肺动脉高压
  • 批准号:
    10642368
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Optimization of Right and Left Ventricular Coupling During Mechanical Circulatory Support
机械循环支持过程中左右心室耦合的优化
  • 批准号:
    10748767
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Recognition of O-GlcNAc Modified Proteins Using Site-Specific Antibodies
使用位点特异性抗体识别 O-GlcNAc 修饰蛋白
  • 批准号:
    10697563
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了